- Home
- SNDX vs AVDL Comparison
SNDX vs AVDL Comparison
Compare SNDX & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- AVDL
- Stock Information
- Founded
- SNDX 2005
- AVDL 2015
- Country
- SNDX United States
- AVDL Ireland
- Employees
- SNDX N/A
- AVDL N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- SNDX Health Care
- AVDL Health Care
- Exchange
- SNDX Nasdaq
- AVDL Nasdaq
- Market Cap
- SNDX 1.6B
- AVDL 1.4B
- IPO Year
- SNDX 2016
- AVDL 1996
- Fundamental
- Price
- SNDX $15.83
- AVDL $10.91
- Analyst Decision
- SNDX Strong Buy
- AVDL Strong Buy
- Analyst Count
- SNDX 11
- AVDL 6
- Target Price
- SNDX $36.00
- AVDL $24.00
- AVG Volume (30 Days)
- SNDX 1.7M
- AVDL 1.5M
- Earning Date
- SNDX 11-05-2024
- AVDL 11-12-2024
- Dividend Yield
- SNDX N/A
- AVDL N/A
- EPS Growth
- SNDX N/A
- AVDL N/A
- EPS
- SNDX N/A
- AVDL N/A
- Revenue
- SNDX $16,000,000.00
- AVDL $138,160,000.00
- Revenue This Year
- SNDX N/A
- AVDL $533.23
- Revenue Next Year
- SNDX $219.92
- AVDL $73.08
- P/E Ratio
- SNDX N/A
- AVDL N/A
- Revenue Growth
- SNDX N/A
- AVDL 1523.50
- 52 Week Low
- SNDX $14.81
- AVDL $10.41
- 52 Week High
- SNDX $25.34
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- SNDX 32.96
- AVDL 31.84
- Support Level
- SNDX $16.03
- AVDL $14.45
- Resistance Level
- SNDX $17.87
- AVDL $16.66
- Average True Range (ATR)
- SNDX 0.93
- AVDL 0.95
- MACD
- SNDX -0.45
- AVDL -0.41
- Stochastic Oscillator
- SNDX 1.26
- AVDL 4.80
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.